Cite
HARVARD Citation
Sheng, C. et al. (2020). Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study). Clinical cardiology. 43 (10), pp. 1055-1063. [Online].